Laurent is a Senior Advisor on the Frazier Life Sciences team and has over 20 years of drug development and commercialization experience in the biopharmaceutical industry.
Laurent joined Frazier Healthcare Partners' Life Sciences team as a Senior Advisor in March 2017, and is also currently Chief Executive Officer at Adverum Biotechologies (NASDAQ: ADVM), a Frazier portfolio company. He was previously CEO of Frazier portfolio company Tobira Therapeutics, which was acquired by Allergan for up to $1.7 billion in 2016. He also serves on the board of directors of Mirum Pharmaceuticals (NASDAQ: MIRM), a Frazier portfolio company developing a novel approach for treating cholestatic liver diseases.
Prior to Tobira, Laurent was chairman and CEO of Jennerex, Inc., a company with a first-in-class oncolytic immunotherapy for Liver Cancer acquired for $150 million by Sillajen. Prior to Jennerex, he was co-founder, president and CEO of Ocera Therapeutics. Laurent has also held senior positions at DuPont-Merck, DuPont Pharmaceuticals, and Hoffmann-La Roche in liver disease, virology and oncology. He launched Sustiva®, the first once-daily anti-HIV and 10th top prescribed specialty drug in 2015, and was involved in the launch of the first protease inhibitor in the United States.
Laurent received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
University of Geneva (M.D.)